Leerink Partnrs Predicts Xeris Biopharma FY2025 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Analysts at Leerink Partnrs issued their FY2025 EPS estimates for shares of Xeris Biopharma in a report issued on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings of ($0.05) per share for the year. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma’s FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.30 EPS.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million.

XERS has been the subject of several other reports. Leerink Partners boosted their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Craig Hallum upped their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. Wall Street Zen cut shares of Xeris Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Oppenheimer upped their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

Xeris Biopharma Price Performance

XERS opened at $4.55 on Monday. The firm has a fifty day moving average price of $4.54 and a 200 day moving average price of $4.10. Xeris Biopharma has a 1 year low of $2.03 and a 1 year high of $6.07. The stock has a market cap of $711.55 million, a P/E ratio of -10.11 and a beta of 0.71.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $34,000. Apella Capital LLC purchased a new stake in shares of Xeris Biopharma in the first quarter valued at about $55,000. Xponance Inc. purchased a new stake in shares of Xeris Biopharma in the first quarter valued at about $57,000. FORA Capital LLC purchased a new stake in shares of Xeris Biopharma in the first quarter valued at about $60,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Xeris Biopharma in the first quarter valued at about $63,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Beth Hecht sold 40,000 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.47% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.